Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY).

Full DD Report for IMMY

You must become a subscriber to view this report.

Recent News from (NASDAQ: IMMY)

FDA revising collaboration with states to ensure access and quality of compounded drugs
In a statement , FDA Commissioner Scott Gottlieb, M.D., outlines the steps the agency is taking to ensure the quality of compounded drugs while enabling access to patients in need. Key points: More news on: Diplomat Pharmacy, AmerisourceBergen Corporation, McKesson Corporation, Healthcare...
Source: SeekingAlpha
Date: September, 07 2018 11:24
Consolidated Research: 2018 Summary Expectations for FTD Companies, PRA Group, Equity Bancshares, ConforMIS, Immune Design, and Imprimis Pharmaceuticals - Fundamental Analysis, Key Performance Indications
NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of FTD Companies, Inc. (NASDAQ:FTD), PRA Group, Inc. (NASDAQ:PRAA), Equity B...
Source: GlobeNewswire
Date: August, 15 2018 07:50


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on IMMY.

About Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY)

Logo for Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY)

Imprimis Pharmaceuticals is a specialty pharmaceutical company focused on the commercial development of compounded drug formulations. Through an exclusive strategic relationship with the largest compounding pharmacy organization in North America, Imprimis expects to use its proprietary Accudel drug delivery technology, coupled with licensed technologies, and proprietary formulations and market data, to identify pharmaceutical development opportunities where there is a significant unmet need for a new drug product. Imprimis is also internally developing non invasive, topically delivered products. Our innovative patented Accudel cream formulation technology is designed to enable highly targeted site specific treatment. Impracor, our lead Phase pain product candidate, utilizes the Accudel platform technology to deliver the active drug, ketoprofen, a non steroidal anti inflammatory drug, through the skin directly into the underlying tissues where the drug exerts its localized anti inflammatory and analgesic effects. We intend to leverage the Accudel platform technology to expand and create a portfolio of topical products for a variety of indications. For more information, visit


Contact Information



Current Management

  • Mark L. Baum / CEO, Principal Executive Officer
  • Dr. Balbir Brar / President
  • Andrew Boll / VP, Fin. amp Acct., Principal Acct. Officer, Principal Fin. Officer
  • Joachim P.H. Schupp / Chief Med. Officer
  • Robert J. Kammer / Chairman
  • Jeffrey Abrams /
  • Stephen Austin /
  • August Bassani /
  • Mark L. Baum /
  • Dr. Paul Finnegan /

Current Share Structure

  • Market Cap: $51,112,967 - 05/16/2018
  • Issue and Outstanding: 20,777,629 - 03/07/2018


Daily Technical Chart for (NASDAQ: IMMY)

Daily Technical Chart for (NASDAQ: IMMY)

Stay tuned for daily updates and more on (NASDAQ: IMMY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: IMMY)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in IMMY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of IMMY and does not buy, sell, or trade any shares of IMMY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: